Healthcare provider profile · identity verified

Timothy B Slama, D.O.

Family Practice · FAIRMONT, MN · NPI 1710299144

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	448	124
Levothyroxine Sodium	Levothyroxine Sodium	382	85
Simvastatin	Simvastatin	371	95
Atorvastatin Calcium	Atorvastatin Calcium	363	99
Omeprazole	Omeprazole	336	77
Amlodipine Besylate	Amlodipine Besylate	297	68
Losartan Potassium	Losartan Potassium	272	76
Hydrochlorothiazide	Hydrochlorothiazide	240	61
Tamsulosin Hcl	Tamsulosin Hcl	227	58
Metoprolol Succinate	Metoprolol Succinate	210	50
Pravastatin Sodium	Pravastatin Sodium	207	50
Gabapentin	Gabapentin	186	37
Pantoprazole Sodium	Pantoprazole Sodium	175	41
Metformin Hcl Er	Metformin Hcl	160	38
Metoprolol Tartrate	Metoprolol Tartrate	160	43
Potassium Chloride	Potassium Chloride	148	31
Rosuvastatin Calcium	Rosuvastatin Calcium	136	37
Metformin Hcl	Metformin Hcl	134	37
Sertraline Hcl	Sertraline Hcl	131	25
Fluticasone Propionate	Fluticasone Propionate	129	38
Escitalopram Oxalate	Escitalopram Oxalate	124	29
Famotidine	Famotidine	121	23
Furosemide	Furosemide	120	34
Eliquis	Apixaban	113	21
Warfarin Sodium	Warfarin Sodium	102	28
Quetiapine Fumarate	Quetiapine Fumarate	97	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	96	22
Allopurinol	Allopurinol	95	29
Clopidogrel	Clopidogrel Bisulfate	85	16
Trazodone Hcl	Trazodone Hcl	85	21
Ventolin Hfa	Albuterol Sulfate	72	13
Albuterol Sulfate Hfa	Albuterol Sulfate	70	32
Montelukast Sodium	Montelukast Sodium	70	15
Lorazepam	Lorazepam	68	18
Atenolol	Atenolol	65	19
Citalopram Hbr	Citalopram Hydrobromide	63	17
Hydralazine Hcl	Hydralazine Hcl	54	suppressed
Bupropion Xl	Bupropion Hcl	53	suppressed
Alprazolam	Alprazolam	51	13
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	51	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	51	15
Glipizide Er	Glipizide	50	15
Tramadol Hcl	Tramadol Hcl	50	11
Donepezil Hcl	Donepezil Hcl	48	suppressed
Glipizide	Glipizide	48	13
Oxybutynin Chloride	Oxybutynin Chloride	46	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	43	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	42	12
Clonazepam	Clonazepam	38	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	37	19
Carvedilol	Carvedilol	36	13
Jardiance	Empagliflozin	35	suppressed
Alendronate Sodium	Alendronate Sodium	34	11
Chlorthalidone	Chlorthalidone	34	12
Nifedipine Er	Nifedipine	34	suppressed
Spironolactone	Spironolactone	34	11
Levetiracetam	Levetiracetam	32	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	29	suppressed
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	28	suppressed
Desmopressin Acetate	Desmopressin Acetate	26	suppressed
Divalproex Sodium Er	Divalproex Sodium	26	suppressed
Paroxetine Hcl	Paroxetine Hcl	25	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	24	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	24	suppressed
Memantine Hcl	Memantine Hcl	24	suppressed
Mirtazapine	Mirtazapine	24	suppressed
Ozempic	Semaglutide	24	suppressed
Incruse Ellipta	Umeclidinium Bromide	22	suppressed
Lactulose	Lactulose	22	suppressed
Nystatin	Nystatin	22	12
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	20	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	20	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Sucralfate	Sucralfate	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Lovastatin	Lovastatin	18	suppressed
Meloxicam	Meloxicam	18	suppressed
Naproxen	Naproxen	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Loperamide	Loperamide Hcl	17	suppressed
Mesalamine	Mesalamine	17	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	17	suppressed
Symbicort	Budesonide/Formoterol Fumarate	17	suppressed
Glimepiride	Glimepiride	16	suppressed
Cephalexin	Cephalexin	15	13
Finasteride	Finasteride	15	suppressed
Midodrine Hcl	Midodrine Hcl	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	14	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	14	suppressed
Ciclopirox	Ciclopirox Olamine	14	suppressed
Sotalol	Sotalol Hcl	14	suppressed
Arnuity Ellipta	Fluticasone Furoate	13	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Risperidone	Risperidone	13	suppressed
Spiriva Handihaler	Tiotropium Bromide	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	12
Enalapril Maleate	Enalapril Maleate	12	suppressed
Kerendia	Finerenone	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Zonisamide	Zonisamide	12	suppressed
Insulin Aspart Flexpen	Insulin Aspart	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Jantoven	Warfarin Sodium	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Levocarnitine	Levocarnitine	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Prednisone	Prednisone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error